Healthcare stocks could be poised to make a big comeback, Morgan Stanley says. Stocks in the sector have lagged behind the S&P 500, gaining just 4.8% for the year. But the bank thinks catalysts like AI and M&A activity could give the sector a fresh boost. There's a big opportunity in one area of the market for investors looking for a bargain: healthcare. The sector looks poised to see a strong rebound despite a mixed performance so far in 2025, analysts at Morgan Stanley said in a recent episode o ...

公司股价表现 - AMTD Digital Inc (NYSE:HKD) 股价大幅上涨93.49%至3.27美元，交易量约为2.8636亿股 [1] - Beneficient (NASDAQ:BENF) 股价上涨57.18%至0.87美元，交易量超过1.1362亿股 [2] - Rani Therapeutics Holdings, Inc (NASDAQ:RANI) 股价上涨50.69%至2.18美元，交易量超过3148万股 [3] - YD Bio Limited Warrants (YDESW) 股价上涨47.06%至1.5美元，交易量为22699股 [4] 公司基本面与催化剂 - AMTD Digital Inc 在截至2025年4月30日的六个月内收入增长1085.9%，主要由于自2024年10月将The Generation Essentials Group合并为子公司 [1] - Beneficient 已重新符合纳斯达克的定期申报和市值要求，但仍需满足每股1美元的买入价规定以避免退市 [2] - Rani Therapeutics Holdings, Inc 将在ObesityWeek® 2025上展示其创新产品RaniPill®胶囊的临床前数据 [3] - YD Bio Limited Warrants 专注于检测和治疗技术，显示出有前景的增长潜力 [4] 市场动态 - 市场环境充满活力，投资者对跨行业公司表现出浓厚兴趣 [5] - 显著的价格变动和交易量凸显了市场对公司发展、投资者情绪和宏观经济因素的反应 [5]

TRENDING: Palantir, Robinhood Earnings Due After Market's Tricky OctoberPfizer (PFE) sued Metsera (MTSR) and Novo Nordisk (NVO) on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller obesity-focused biotech company.The move is the second jab in an escalating battle pitting Pfizer and Novo Nordisk. The first came Thursday when Novo issued an unsolicited bid to buy Metsera, a month after Pfizer struck a deal to acquire Metsera for $4.9 billion.Pfizer's lawsuit asserts that Metsera breached ...

公司概况 - MoonLake Immunotherapeutics（MLTX）是一家瑞士临床阶段生物技术公司，专注于由白细胞介素-17（IL-17）驱动的炎症性疾病，特别是在皮肤病学和风湿病学领域 [1] 诉讼核心指控 - 公司在2024年3月10日至2025年9月29日的类别期间，被指控就其主要药物候选物SLK的疗效误导投资者 [1] - 指控称公司未披露关键信息：SLK与已获FDA批准的BIMZELX药物具有相同的分子靶点（炎症细胞因子IL-17A和IL-17F）[3] - 指控称公司关于SLK的纳米抗体结构相较于BIMZELX的单克隆抗体结构能带来临床优势的说法缺乏合理依据 [3] 关键事件与市场影响 - 2025年9月28日，公司公布了其VELA项目三期临床试验的第16周结果，显示SLK未能证明相对于BIMZELX具有竞争优势的疗效 [4] - 在此结果公布后，公司股价暴跌，每股下跌55.75美元，跌幅达89.9%，于2025年9月29日收于每股6.24美元 [4] 法律程序进展 - 针对MoonLake Immunotherapeutics的集体诉讼已提起，股东若希望作为首席原告，必须在2025年12月15日前向法院提交文件 [5]

Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers (DFU) patients  Preparing to submit Investigational New Drug applications for the treatment of psoriasis with CYPS317 and the treatment of multiple sclerosis with CYMS101 HOUSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issu ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

作者背景与资讯服务 - 作者为生物技术顾问 在生物技术、医疗保健和制药行业拥有超过5年研究经验 [1] - 已撰写超过1,000家公司的详细报告 [1] - 主导名为Haggerston BioHealth的投资团体 服务对象涵盖生物技术投资新手和经验丰富的投资者 [1] 资讯服务内容 - 每周通讯提供生物技术、制药和医疗保健行业股票的动态信息 [1] - 分析推动估值的关键趋势和催化剂 [1] - 服务内容包括提供需关注的事件、买入和卖出评级 [1] - 提供所有大型制药公司的产品销售额和预测、综合财务报表、贴现现金流分析和逐市场分析 [1]

While many investors focus on semiconductors and AI or the growth sector, one of my Economic Modern Family members has been busy.The Biotech Sector ETF (NASDAQ: IBB), has made new multi-year highs. We cannot say new all-time highs as that was made in 2021 during Covid.However, we can discount that unusual time and safely say the Biotech Sector ETF (IBB) is on a tear and could very well continue. Sign up for our FREE newsletter and receive our best trading ideas and research Leave this field empty ...

SAN FRANCISCO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or “SLK”), its highly anticipated treatment for patients with skin disease (hidradenitis suppurativa or “HS”). On this announcement, MoonLake investors saw the price of their shares crater $55.75, or about 90%, on Se ...

公司人事任命 - Phio Pharmaceuticals Corp (NASDAQ: PHIO) 宣布任命 David H Deming 为董事会首席独立董事 [1] - David Deming 在投资银行和资产管理领域拥有超过30年经验 [2] - David Deming 曾在摩根大通工作超过27年，其中最后12年领导投资银行部的医疗健康团队，并于2025年2月加入Phio董事会，担任提名委员会成员 [2] 公司核心技术与产品管线 - 公司是一家临床阶段的siRNA生物制药公司，专注于开发其专有的INTASYL®基因沉默技术，以消除癌症 [1][4] - INTASYL®化合物旨在增强人体免疫细胞，以更有效地杀死癌细胞 [4] - 公司主要临床项目是INTASYL化合物PH-762，该药物通过沉默与多种皮肤癌相关的PD-1基因发挥作用 [4] - 正在进行的1b期临床试验 (NCT 06014086) 正在评估PH-762用于治疗皮肤鳞状细胞癌、黑色素瘤和默克尔细胞癌，PH-762是皮肤癌的潜在非手术治疗方案 [4] 公司战略与前景 - 首席执行官兼董事会主席Robert Bitterman表示，David Deming在生物制药领域的丰富经验将为公司推进其旨在消除癌症的基因沉默技术提供宝贵资源 [3]